Insider Selling: CytomX Therapeutics Inc (CTMX) Insider Sells 6,526 Shares of Stock

CytomX Therapeutics Inc (NASDAQ:CTMX) insider Sean A. Mccarthy sold 6,526 shares of the business’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $25.01, for a total value of $163,215.26. Following the completion of the sale, the insider now owns 11,169 shares in the company, valued at $279,336.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of CytomX Therapeutics Inc (NASDAQ:CTMX) opened at $24.96 on Thursday. CytomX Therapeutics Inc has a one year low of $10.64 and a one year high of $25.60. The stock has a market capitalization of $958.68 and a price-to-earnings ratio of -15.90.

Several large investors have recently added to or reduced their stakes in CTMX. Legal & General Group Plc raised its stake in shares of CytomX Therapeutics by 28.6% during the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 1,434 shares during the period. Macquarie Group Ltd. bought a new stake in shares of CytomX Therapeutics during the 3rd quarter valued at $107,000. Cubist Systematic Strategies LLC bought a new stake in shares of CytomX Therapeutics during the 2nd quarter valued at $174,000. Voya Investment Management LLC bought a new stake in shares of CytomX Therapeutics during the 2nd quarter valued at $203,000. Finally, Nationwide Fund Advisors raised its stake in shares of CytomX Therapeutics by 39.4% during the 2nd quarter. Nationwide Fund Advisors now owns 16,365 shares of the biotechnology company’s stock valued at $254,000 after purchasing an additional 4,622 shares during the period. Institutional investors own 63.13% of the company’s stock.

Several analysts have issued reports on CTMX shares. BidaskClub lowered CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Cowen reiterated an “outperform” rating on shares of CytomX Therapeutics in a research note on Thursday, October 5th. ValuEngine lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Nomura boosted their price objective on CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a research note on Wednesday, October 4th. Finally, Cantor Fitzgerald initiated coverage on CytomX Therapeutics in a research note on Monday, October 23rd. They set an “overweight” rating and a $35.00 price objective on the stock. Two analysts have rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $32.78.

COPYRIGHT VIOLATION WARNING: This report was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://sportsperspectives.com/2018/01/11/insider-selling-cytomx-therapeutics-inc-ctmx-insider-sells-6526-shares-of-stock.html.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply